Delivery of macromolecules into the central nervous system via the bloodstream
Номер патента: EP3927366A1
Опубликовано: 29-12-2021
Автор(ы): Irvin S.Y. Chen, Jing Wen, Masakazu Kamata, Yunfeng Lu
Принадлежит: UNIVERSITY OF CALIFORNIA
Опубликовано: 29-12-2021
Автор(ы): Irvin S.Y. Chen, Jing Wen, Masakazu Kamata, Yunfeng Lu
Принадлежит: UNIVERSITY OF CALIFORNIA
Реферат: CNS metastases are a major cause of cancer deaths with few therapeutic options for treatment. Monoclonal antibody-based therapy is one of the most successful therapeutic strategies for cancer; however, its efficacy is limited against CNS metastases due to insufficient CNS delivery. Here, we show significantly improved antibody delivery to the CNS using novel timed-release nanocapsules that encapsulate individual antibodies within acrosslinked phosphorylcholine polymer and gradually release cargo through hydrolysable crosslinkers. A single course of rituximab (RTX) nanocapsule treatment elevates RTX levels in the CNS by nearly 10-fold compared to native RTX. We improved control of CNS metastases in a murine xenograft model of non-Hodgkin lymphoma; moreover, using a xenograft humanized BLT mouse model, lymphomas were eliminated with a single course of RTX nanocapsule treatment. This approach is useful for treatment of cancers with CNS metastases and is generalizable for delivery of any antibody to the CNS.
Delivery of macromolecules into the central nervous system via the bloodstream
Номер патента: WO2020172263A1. Автор: Yunfeng Lu,Irvin S.Y. Chen,Jing Wen,Masakazu Kamata. Владелец: The Regents of the University of California. Дата публикации: 2020-08-27.